Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
The American Society for Radiation Oncology today issued a new clinical guideline for the management of oropharyngeal cancer.
ANGLE plc, the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE’s Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference 2017, in Washington DC.
Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute.
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy, has shown early promise for the treatment of recurrent lung cancer, according to new research from The University of Texas MD Anderson Cancer Center.
Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma — the most common head and neck cancer and the second-most common skin cancer, according to a new study by cancer researchers at the UCLA School of Dentistry.
Cervical cancer is the leading cause of cancer deaths for women low- and middle-income countries, including Botswana, where 75 percent of cervical cancer patients suffer from advanced forms of the disease.
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
A team of researchers at the Research Institute of the McGill University Health Centre has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use.
Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.
Researchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.
A new study suggests the possibility of predicting at its earliest stages when a type of head and neck cancer will come back.
A number of genetic variants associated with susceptibility to oral cavity and pharyngeal cancer have been described in an international study published in the journal Nature Genetics.
Results of the largest Canadian clinical trial to date comparing standard treatment for locally advanced squamous cell head and neck cancer with an experimental treatment, did not show the new treatment is superior.
Patients wait an average of four months before seeking a cancer diagnosis, researchers report at the ESMO ASIA 2016 Congress in Singapore.
Researchers at the University of Cincinnati have discovered that an ion channel, active within T cells (white blood cells), could be targeted to reduce the growth of head and neck cancers.
When Kerstin Stenson, MD, describes the innovative technique she is helping develop to fight cancer, it seems like she's describing a Tom Clancy military espionage novel.
A study led by UCLA researchers found that in people with breathing difficulties caused by phrenic nerve injury surgical reconstruction of the nerve can lead to significant improvement in breathing and an increase in regular physical activities.
Sanford Health has opened another clinical trial exploring the power of the body's immune system to fight cancer.
A nationwide study of head and neck cancers in France has revealed that the true burden of the disease is underestimated by at least one-third, and that head and neck cancers carry a very high risk of secondary primary cancers, according to two presentations at the ESMO 2016 Congress in Copenhagen.
The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen.